Moreover, as overviewed above, ALP is regulated in various ways by PD gene products—including LRRK2, VPS35, ATP13A2, GCase, and other risk factors not mentioned in this review—and among these, not only GCase (activator, ambroxol) but also LRRK2 (inhibitor) are being targeted in clinical trials (208). This evidence concerns the gene LRRK2 and Parkinson disease.